Mersana’s innovative platforms are a highly efficient product engine that is building a robust discovery pipeline for us and our partners. Our ADCs in preclinical and clinical trials are first-in-class molecules that target multiple tumor types with high unmet medical need and have exhibited improved safety and efficacy compared to ADCs developed using first-generation technology. Our lead asset, upifitamab rilsodotin (UpRi), is a first-in-class Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registration strategy, in patients with platinum-resistant ovarian cancer as well as the expansion portion of a Phase 1 proof-of-concept clinical study in patients with NSCLC adenocarcinoma. Our next clinical stage ADC, XMT-1592, a Dolasynthen ADC-targeting NaPi2b expressing tumors entered the clinic in May 2020.

ADC Program	Target	Indication	Platform	Discovery	Preclinical	P1	P1	P2	P3
Clinical
upifitamab rilsodotin (UpRi)*	NaPi2b	Ovarian Cancer	Dolaflexin
XMT-1536*	NaPi2b	NSCLC Adenocarcinoma	Dolaflexin
Preclinical
XMT-1592*	NaPi2b	Ovarian Cancer NSCLC Adenocarcinoma	Dolasynthen
Discovery
XMT-1660	B7-H4	Multiple Solid Tumors	Dolasynthen
XMT-2056	Undisclosed	Undisclosed	Immunosynthen
Multiple Programs	Undisclosed	Undisclosed	Immunosynthen
Multiple Programs	Undisclosed	Undisclosed	Dolaflexin or Dolasynthen
Platform Collaborations
Multiple	Multiple	Undisclosed	Dolaflexin
ASN004	5T4	Undisclosed	Dolaflexin

Drug	Indication	Stage
Clinical
upifitamab rilsodotin (UpRi)*	NaPi2b	Ovarian Cancer	Dolaflexin	P1
XMT-1536*	NaPi2b	NSCLC Adenocarcinoma	Dolaflexin	Preclinical
Preclinical
XMT-1592*	NaPi2b	Ovarian Cancer NSCLC Adenocarcinoma	Dolasynthen	Preclinical
Discovery
XMT-1660	B7-H4	Multiple Solid Tumors	Dolasynthen	Discovery
XMT-2056	Undisclosed	Undisclosed	Immunosynthen	Discovery
Multiple Programs	Undisclosed	Undisclosed	Immunosynthen	Discovery
Multiple Programs	Undisclosed	Undisclosed	Dolaflexin or Dolasynthen
Platform Collaborations
Multiple	Multiple	Undisclosed	Dolaflexin	Discovery
ASN004	5T4	Undisclosed	Dolaflexin	Discovery

*NaPi2b antibody used in UpRi (formerly XMT-1536) and XMT-1592 is in-licensed from Recepta Biopharma. Recepta has rights to commercialize UpRi and XMT-1592 in Brazil.